Stay updated with breaking news from Ryan Sullivan. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Median 46 months follow up from Phase 2 trial confirms median OS of 16.8 months, with landmark OS rates approximately double historical rates in metastatic uveal melanoma population ... | April 18, 2023
The mRNA cancer vaccine combined with immunotherapy improved survival rates for stage 3 and 4 melanoma, Moderna and Merck announced. Here's what to know.
The experimental mRNA vaccine works in combination with Merck's immunotherapy to fight melanoma.
The findings of the recent trial suggest that adding a personalized cancer vaccine to antibody-based immunotherapy could prolong the time patients have without death or the cancer's return.
'From a general cancer therapeutic standpoint, this is a potential major breakthrough'